Esther Drill, DrPH

Principal Biostatistician

Esther Drill

Office Phone



Columbia University

Dr. Drill’s area of expertise lies in using statistical and computational approaches to applied research in cancer genomics. She has considerable experience with analyses of data from targeted sequencing platforms (including MSK IMPACT and HEME-PACT), as well as individual genome-wide platforms, such as RNA-Seq, gene expression arrays, and methylation assays. In addition, she has particular experience with integrative genomic analysis incorporating multiple genomic platforms, including large data sets from The Cancer Genome Atlas.

She also collaborates with Lymphoma department physicians on clinical trial and observational study design and analysis.



Selected peer-reviewed publications:


  1. Pietzak EJ, Bagrodia A, Cha EK, Drill EN, Iyer G, Isharwal S, Ostrovnaya I, Baez P, Li Q, Berger MF, Zehir A, Schultz N, Rosenberg JE, Bajorin DF, Dalbagni G, Al-Ahmadie H, Solit DB, Bochner BH. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. European Urology. 2017 Dec; 72(6): 952-959. 


  1. Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E*, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM; Cancer Genome Atlas Network, Stuart JM, Benz CC, Laird PW. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell. 2018 Apr 5; 173(2): 291-304.


  1. Hmeljak J, Sanchez-Vega F, Hoadley, KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, …, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi, M. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discovery. 2018 December; 8(12);1548-1565.


  1. Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 March 13; 567; 521-524.


  1. Wang T, Drill E, Vakiani E, Pak LM, Boerner T, Askan G, Schvartzman JM, Simpson AL, BZhou Y, Basturk O, Askan G, Pak LM, Vakiani E, Wang T, Do RKG, Simpson AL, Jarnagin W, Sigel CS. Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma. Human Pathology 2019 Sept; 91; 19-25.


*Co-first author